Literature DB >> 24045166

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

Justyna Kmiecik1, Aurélie Poli, Nicolaas H C Brons, Andreas Waha, Geir Egil Eide, Per Øyvind Enger, Jacques Zimmer, Martha Chekenya.   

Abstract

We characterized GBM patients' tumor and systemic immune contexture with aim to reveal the mechanisms of immunological escape, their impact on patient outcome, and identify targets for immunotherapy. Increased CD3(+) T-cell infiltration was associated with prolonged survival independent of age, MGMT promoter methylation and post-operative treatment that implies potential for immunotherapy for GBM. Several mechanisms of escape were identified: within the tumor microenvironment: induced CD8(+)CD28(-)Foxp3(+) Tregs that may tolerize antigen presenting cells, elevated CD73 and CD39 ectonucleotidases that suppress T-cell function, and at the systemic level: elevated IL-10 levels in serum, diminished helper T-cell counts, and upregulated inhibitory CTLA-4.
© 2013. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antigen presenting cells; GBM; Regulatory T cells; Tumor infiltrating cells

Mesh:

Substances:

Year:  2013        PMID: 24045166     DOI: 10.1016/j.jneuroim.2013.08.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  160 in total

1.  Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells.

Authors:  Gregory J Baker; Maria G Castro; Pedro R Lowenstein
Journal:  J Vis Exp       Date:  2015-11-28       Impact factor: 1.355

2.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.

Authors:  Ganesh Rao; Khatri Latha; Martina Ott; Aria Sabbagh; Anantha Marisetty; Xiaoyang Ling; Daniel Zamler; Tiffany A Doucette; Yuhui Yang; Ling-Yuan Kong; Jun Wei; Gregory N Fuller; Fernando Benavides; Adam M Sonabend; James Long; Shulin Li; Michael Curran; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2020-06-18       Impact factor: 12.531

Review 3.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

4.  CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.

Authors:  Jillian Rosenberg; Jun Huang
Journal:  Curr Opin Chem Eng       Date:  2017-12-14       Impact factor: 5.163

5.  Analysis of immunobiologic markers in primary and recurrent glioblastoma.

Authors:  Maryam Rahman; Jesse Kresak; Changlin Yang; Jianping Huang; Wesley Hiser; Paul Kubilis; Duane Mitchell
Journal:  J Neurooncol       Date:  2018-01-04       Impact factor: 4.130

Review 6.  FOXOs in cancer immunity: Knowns and unknowns.

Authors:  Youcai Deng; Fangjie Wang; Tiffany Hughes; Jianhua Yu
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

7.  Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues.

Authors:  Tianyu He; Egidio Brocca-Cofano; Delbert G Gillespie; Cuiling Xu; Jennifer L Stock; Dongzhu Ma; Benjamin B Policicchio; Kevin D Raehtz; Charles R Rinaldo; Cristian Apetrei; Edwin K Jackson; Bernard J C Macatangay; Ivona Pandrea
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

8.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

9.  FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.

Authors:  Jun Yan; Ling-Yuan Kong; Jiemiao Hu; Konrad Gabrusiewicz; Denada Dibra; Xueqing Xia; Amy B Heimberger; Shulin Li
Journal:  J Natl Cancer Inst       Date:  2015-05-13       Impact factor: 13.506

Review 10.  The Role of Checkpoint Inhibitors in Glioblastoma.

Authors:  Kunal Desai; Anne Hubben; Manmeet Ahluwalia
Journal:  Target Oncol       Date:  2019-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.